Stocks · News reference
Collegium Pharmaceutical Announces Acceptance of Seven ADHD Portfolio Abstracts for Scientific Congresses
Collegium Pharmaceutical, Inc. announced that seven abstracts from its ADHD portfolio have been accepted for presentation at two upcoming scientific congresses.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Needham Maintains Buy Rating on Collegium Pharmaceutical, Lowers Price Target
Needham & Company maintained its 'Buy' rating on Collegium Pharmaceutical while adjusting its price target from $46 to $44.
Collegium Pharmaceutical Q3 2026 Earnings Call Transcript
Collegium Pharmaceutical (NASDAQ:COLL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by
Collegium Pharmaceutical Reports Third Quarter 2026 Financial Results
Collegium Pharmaceutical announced its financial results for the third quarter ended September 30, 2026, and reaffirmed its full-year 2026 financial guidance.
8-K filing — COLLEGIUM PHARMACEUTICAL, INC (COLL)
Filed: 2026-11-05 AccNo: 0001628280-26-070585 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Collegium Pharmaceutical Expands Partnership with Boston Legacy FC
Collegium Pharmaceutical has expanded its partnership with Boston Legacy FC to include community-based programming across Massachusetts, ahead of the company's planned headquarters relocation to Boston in 2027.